Interferon-α/thalidomide

Reactions 1423 - 13 Oct 2012 S Interferon-α/thalidomide Neutropenia: case report A 56-year-old woman developed neutropenia while receiving interferon-α for the treatment of hereditary haemorrhagic teleangiectasis. She subsequently developed neutropenia during treatment with thalidomide [Myrin]. The woman had hypochromic anaemia and had been experiencing recurrent nose bleeds since the age of 35 years. In 2011, she began first-line therapy with interferon-α at a dosage of 1.5 million units 3 times per week. During the first 3 injections, she developed pronounced myelosuppression with significantly reduced neutrophil and platelet counts. Bone marrow examination revealed a significant iron deficit, with only 4% sideroblasts. A biopsy showed depression of granulopoiesis with an absence of dyeable stromal iron. Interferon-α was discontinued, and the woman received erythrocyte transfusions. She started receiving thalidomide 100mg daily. One month later, she developed neutropenia, and the dosage of thalidomide was decreased to 100mg every second day [outcome not stated]. Author comment: This patient experienced changes in white blood cell count, neutrophil granulocytes and thrombocytes during the first few days of treatment by interferon at a dosage of 1.5 million units three times a week. Unusually great reduction resulted in discontinuation of interferon-α after 3 injections. Adam Z, et al. Teleangiectasia hereditaria haemorrhagica - Osler-Weber-Rendu syndrome. Case study and treatment experience. Vnitrni lekarstvi 58: 477-489, No. 6, Jan 2012 [Czech; summarised from a translation] - Czech Republic 803078380 1 Reactions 13 Oct 2012 No. 1423 0114-9954/10/1423-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload
lamdan
Category

Documents
view
213
download
0

Embed Size (px):

Transcript of Interferon-α/thalidomide

Reactions 1423 - 13 Oct 2012

SInterferon-α/thalidomide

Neutropenia: case reportA 56-year-old woman developed neutropenia while

receiving interferon-α for the treatment of hereditaryhaemorrhagic teleangiectasis. She subsequently developedneutropenia during treatment with thalidomide [Myrin].

The woman had hypochromic anaemia and had beenexperiencing recurrent nose bleeds since the age of35 years. In 2011, she began first-line therapy withinterferon-α at a dosage of 1.5 million units 3 times perweek. During the first 3 injections, she developedpronounced myelosuppression with significantly reducedneutrophil and platelet counts. Bone marrow examinationrevealed a significant iron deficit, with only 4% sideroblasts.A biopsy showed depression of granulopoiesis with anabsence of dyeable stromal iron.

Interferon-α was discontinued, and the woman receivederythrocyte transfusions. She started receiving thalidomide100mg daily. One month later, she developed neutropenia,and the dosage of thalidomide was decreased to 100mgevery second day [outcome not stated].

Author comment: This patient experienced changes inwhite blood cell count, neutrophil granulocytes andthrombocytes during the first few days of treatment byinterferon at a dosage of 1.5 million units three times a week.Unusually great reduction resulted in discontinuation ofinterferon-α after 3 injections.Adam Z, et al. Teleangiectasia hereditaria haemorrhagica - Osler-Weber-Rendusyndrome. Case study and treatment experience. Vnitrni lekarstvi 58: 477-489, No.6, Jan 2012 [Czech; summarised from a translation] - Czech Republic 803078380